ERLIN1

Across TCGA pan-cancer cohorts, ERLIN1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ERLIN1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ERLIN1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ERLIN1 is over-expressed in tumor, although a few such as OV show the opposite, repressed pattern.

LSCC, COAD, and PDAC are the cancer types where ERLIN1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERLIN1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	III,IV	+0.452	<.001	8	view →
COAD	All	All	+0.099	.003	4	view →
PDAC	All	II,III,IV	+0.230	.009	3	view →
OV	All	All	−0.506	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ERLIN1–LSCC

Open the LSCC breakdown →